Also known as Trulicity · LY2189265
Once-weekly GLP-1 receptor agonist built as an Fc-fusion protein (Trulicity) — FDA-approved for type 2 diabetes since 2014, with cardiovascular-outcomes data from REWIND.
Research refreshed
Dulaglutide solves the half-life problem a different way from semaglutide. Instead of attaching a fatty acid to a synthetic peptide, it fuses two copies of a DPP-4-resistant GLP-1 analog to a modified human IgG4 Fc fragment, producing a ~59.7 kDa recombinant protein with a half-life of about five days. Eli Lilly’s Trulicity was approved by the FDA in September 2014 for type 2 diabetes; the REWIND trial (Lancet 2019) later showed a 12% reduction in major adverse cardiovascular events, extending the label to cardiovascular risk reduction.
Native GLP-1 lasts about two minutes in circulation — cleaved by DPP-4 and cleared by the kidney. The incretin field found three engineering answers. Liraglutide and semaglutide attach a fatty acid so the peptide rides on albumin. Albiglutide fused GLP-1 to albumin directly. Dulaglutide fuses it to an antibody fragment: each of its two identical chains is a GLP-1(7–37) analog with substitutions that block DPP-4 cleavage, joined by a short peptide linker to a modified IgG4 Fc domain engineered to minimize immune effector function.
That makes it a biologic rather than a synthetic peptide — expressed in mammalian cell culture, glycosylated, and far too large for solid-phase synthesis. The AWARD Phase 3 program established its glycemic efficacy at 0.75 mg and 1.5 mg weekly, and AWARD-11 added 3.0 mg and 4.5 mg doses (approved 2020). Weight loss is modest by current standards — a few kilograms on average — which is why it is positioned as a diabetes drug and has no obesity indication.
Its landmark is REWIND (Gerstein et al., Lancet 2019): 9,901 adults with type 2 diabetes followed for a median 5.4 years, most of them without established cardiovascular disease. Dulaglutide reduced major adverse cardiovascular events by 12% (hazard ratio 0.88, 95% CI 0.79–0.99), supporting an indication that covers primary as well as secondary prevention. It is also approved for type 2 diabetes in patients aged 10 and older. Dulaglutide now serves as the active comparator the newer agents are measured against — including tirzepatide’s cardiovascular-outcomes trial, SURPASS-CVOT.
GLP-1 receptor agonism → glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and reduced appetite. The Fc domain enlarges the molecule beyond renal filtration and recycles it through the neonatal Fc receptor, extending exposure to once-weekly.
Behind every vial of Dulaglutide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Dulaglutide, specifically, is brought into being.
On paper, Dulaglutide weighs in at roughly 59,700 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Dulaglutide is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later. It also carries fatty-acid acylation, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Dulaglutide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Dulaglutide proves itself: identity confirmed by mass spectrometry against its ~59,700 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Dulaglutide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Dulaglutide to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Dulaglutide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist from Eli Lilly, FDA-approved since 2014 for type 2 diabetes and for reducing cardiovascular risk in adults with type 2 diabetes.
Both are once-weekly GLP-1 agonists, but they are built differently. Semaglutide is a ~4.1 kDa synthetic peptide carrying a fatty-acid chain that binds albumin. Dulaglutide is a ~59.7 kDa recombinant protein — two GLP-1 analog chains fused to an antibody Fc fragment. Semaglutide produces substantially more weight loss and has an obesity indication; dulaglutide does not.
It is a fusion protein rather than a synthetic peptide: the GLP-1-like portion is a peptide sequence, but it is expressed as part of a larger Fc-fusion in mammalian cells and cannot be made by solid-phase synthesis.
Modestly — trials report average losses of a few kilograms, increasing with dose. It is not approved for weight management.
In 9,901 adults with type 2 diabetes followed for a median 5.4 years, dulaglutide reduced major adverse cardiovascular events by 12% versus placebo (HR 0.88, 95% CI 0.79–0.99). Most participants had risk factors rather than established cardiovascular disease.
Mainly gastrointestinal — nausea, diarrhea, vomiting and reduced appetite. The label carries the class boxed warning about thyroid C-cell tumors seen in rodent studies. This page is a research reference, not medical advice.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.